NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,169.60
- Market cap
- ₹52,302 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 46.3×Sector 42.0×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.
Gland Pharma Results Update
Gland Pharma reported Q2FY27 revenue of Rs. 18,336 Mn, up 23% YoY, and PAT of Rs. 2,908 Mn, up 58% YoY. The press release accompanies its quarterly financial results filing.
Gland Pharma Q2 FY27 Results: Net Profit ₹290.8 Cr, Up 58.3% YoY
Gland Pharma Ltd reported revenue from operations of ₹1,834 Cr (+23.3% YoY) and net profit of ₹290.8 Cr (+58.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹290.8 Cr · +58.3% YoY
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.
Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Other results update announcements
All →Data Patterns (India) Results Update
Data Patterns' Q2 FY27 revenue fell 56.7% to ₹133.25 Crore, with PAT at ₹21.97 Crore. Order book including negotiated orders reached ₹2,697.83 Crore.
Dhabriya Polywood Results Update
Dhabriya Polywood reported Q2 FY27 revenue of ₹77.8 crore, up 16.1% YoY, and PAT of ₹9.2 crore. It also cited an order book above ₹240 crore.
Supriya Lifescience Results Update
Supriya Lifescience's Q2 FY27 revenue rose 3.2%, but EBITDA and PAT fell sharply. Ambernath ramp-up costs and LATAM regulatory shifts hurt margins.
Bluspring Enterprises Results Update
Bluspring Enterprises' press release shows Q2 FY27 revenue up 49% YoY and PAT up 95%. Results exclude foundit, and no event value is assigned.
Capital India Finance Results Update
Capital India Finance's H1 FY27 press release shows standalone income up 44% to Rs 145.32 Crore. Disbursements rose 39% and AUM grew 25% year-on-year.
Anawil Wire & Engineering Results Update
Anawil reported H1FY27 revenue of Rs 153.97 Crore, up 272.2% YoY. PAT rose 539.3% to Rs 14.39 Crore; FY27 guidance is Rs 450-500 Crore revenue.